Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AspenBio Pharma, a bio-pharmaceutical company, has received a notice of allowance from the US Patent and Trademark Office for the company's US patent application directed to methods relating to its appendicitis diagnostic technology.
Subscribe to our email newsletter
According to the company, the newly allowed claims include subject matter covering aspects of blood-based appendicitis testing.
A notice of allowance generally completes the substantive examination of a patent application. Following a notice of allowance, the normal process which results in final issuance of a US patent involves several administrative steps that are typically completed in due course following issuance of this notice.
Richard Donnelly, president and CEO of AspenBio Pharma, said: “This represents a major milestone in the development of our intellectual property for the appendicitis diagnostic technology. This official notice from the Patent Office represents a considerable achievement for our company and our goals.
“The issuance of this notice represents recognition of the patentability of our innovative technology and enhances the value of this important asset.”